Dermoveyt ™ 0,05% 25g of the cream in the tube

The instruction for medical use of Dermoveyt™ medicine the Trade name of Dermoveyt™ the International unlicensed name Klobetazol Lekarstvennaya a form Cream for external use of 0.05% 25 g Structure of 1 g of cream contains active agent - a klobetazol of propionate of 500 mkg, excipients: glyceryl monostearate 40-55, arlatset 165, substitute of beeswax 6621, cetostearyl alcohol, propylene glycol, chlorocresol, sodium citrate, citric acid monohydrate, water purified. The description Uniform cream from white till whitish color Pharmacotherapeutic group Corticosteroids with high activity. ATC D07AD01 code the Pharmacological Pharmacokinetics At properties topical administration of drug, especially during the using of an occlusive bandage or injuries of skin, absorption of a klobetazol of propionate with development of system side effects of glucocorticoids is possible. Klobetazola propionate has smaller ability to contact proteins of blood plasma in comparison with a hydrocortisone, but big elimination half-life. The rest - kidneys is metabolized, mainly, by a liver. It is removed with urine. A pharmacodynamics Glucocorticoid drug for external use. Has anti-inflammatory and antiallergic effect, causes vasoconstriction and increase in synthesis of collagen. Eliminates hypostasis, hyperaemia and an itching in the site of application. Indications – – eczema (refractory forms) – red flat deprive psoriasis (except for widespread blyashechny psoriasis) – a diskoidny lupus erythematosus – other skin diseases resistant to therapy of less active glucocorticoids the Route of administration and doses Cream should be applied with a thin layer on affected areas of skin of 1-2 times/days before improvement. At permanent damages of skin, especially in case of a hyperkeratosis, anti-inflammatory action of Dermoveyta™ can be strengthened by use of an occlusive bandage (imposing of a bandage for 1 night can be rather effective). When changing an occlusive bandage the skin needs to be cleaned. In the absence of effect of use of drug within 4 weeks it is necessary to consult with the doctor for the purpose of specification of the diagnosis. Drug is recommended for short-term use. If necessary carrying out short repeated courses is possible. If long-term treatment is required, it is recommended to use less strong means. Side effects local reactions: - at long and intensive treatment - atrophic changes on skin - striya, thinning of skin, expansion of superficial blood vessels, pigmentation disturbances, a hypertrichosis system reactions: - at prolonged use in high doses the emergence of symptoms of a hypercorticoidism is possible, especially children of the Contraindication have a hypersensitivity to drug – eels ordinary – a rozatsea – perioral dermatitis – a perianal and genital itching – primary viral infections of skin (herpes simplex, chicken pox) – primary bacterial infections of skin – primary skin defeats of a fungal etiology – a dermatosis at children aged till 1 year, including dermatitis and an intertrigo Medicinal interactions Medicinal interaction of the drug Dermoveyt™ is not described Special instructions At treatment of such diseases as psoriasis, a diskoidny lupus erythematosus, eczema it must be kept in mind that on face skin there are more significant atrophic changes, than on other parts of the body. Use of drug at treatment of psoriasis demands attentive observation of the patient for prevention of a recurrence, development of tolerance, developing of widespread pustulous psoriasis and development of local or system reaction because of disturbance of barrier function of skin. In case of accession of an infection of Dermoveyt™ it is necessary to cancel and appoint the corresponding therapy. At emergence of signs of hypersensitivity to drug the therapy should be stopped immediately. At prolonged continuous use of drug the suppression of function of a hypophysis and bark of adrenal glands is possible. If the week dose of drug at treatment of adult patients does not exceed 50 g, then this systemic action most often is temporary, and function of a hypophysis and bark of adrenal glands is normalized after the termination of a course of steroid therapy. Use of occlusive bandages increases absorption of GKS for external use. When putting cream on eyelids it is necessary to take precautionary measures in order to avoid hit of drug in eyes. Use in pediatrics At children of a diaper can work also as occlusive bandages. Pregnancy and the period of a lactation is not recommended use of Dermoveyta™ for an appreciable length of time at pregnant women. There are no data on safety of use of drug in the period of a lactation. The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms does not affect ability to drive the car or other mechanisms. Overdose Emergence of acute overdose is improbable. In case of overdose or the wrong use there can be signs of a hypercorticoidism that demands drug withdrawal. A form of release and packing On 25 g in tubas aluminum with internal varnish coating, sealed by membranes and closed by the screw-on plastic covers. On 1 tuba together with the instruction for use in the state and Russian languages place in a pack from cardboard. To Store storage conditions at a temperature not above 30 °C. To store out of children's reach! 2 years not to use a period of storage after the expiry date specified on packing. Prescription status According to the prescription the Production of the GlaksoSmitKlyayn Pharmasyyutikalz Company Producer, Poland. (GlaxoSmithKline Pharmaceuticals S.A. 189 Grunwaldzka str, Poznan, Poland) Dermoveyt™ are the registered trade mark of GlaxoSmithKline group of companies. The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods): Representative office of GlaksoSmitKlyayn Export Ltd in Kazakhstan 050059, Almaty, Furmanov St., 273 Phone number: +7 727 258 28 92, +7 727 259 09 96 Fax number: + 7 727 258 28 90 E-mail address: zaira.k.smailova@gsk.com